Renal Denervation in Heart Failure Patients With Preserved Ejection Fraction (RESPECT-HF)

NCT02041130 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2015-01-16

No results posted yet for this study

Summary

Investigators will test a new approach to a form of heart failure (HF) with no current treatment proven to reduce death rates or hospitalisations. Over a third of HF cases have preserved ejection fraction (HFPEF) often on a background of high blood pressure (BP). These "stiff" hearts pump strongly but fill inefficiently resulting in poor exercise capacity and high death rates. Treatments that help when heart pumping action is poor are of no benefit in HFPEF. Recently a simple catheter procedure removing excess nerve signals to and from the kidneys ("renal denervation"; RDN) has been able to reduce BP in patients with high BP resistant to multi-drug treatment. Through removing excess nervous drive to the kidneys, heart and circulation this treatment has promise in HF. The investigators will compare effects of RDN and standard medical treatment on heart function, exercise capacity and quality of life in 144 patients with HFPEF

Conditions

Interventions

DEVICE

Renal Denervation

Sponsors & Collaborators

  • University of Otago

    collaborator OTHER
  • Wellington Hospital

    collaborator OTHER_GOV
  • University of Auckland, New Zealand

    collaborator OTHER
  • Monash University

    collaborator OTHER
  • Tan Tock Seng Hospital

    collaborator OTHER
  • Changi General Hospital

    collaborator OTHER
  • Singapore Clinical Research Institute

    collaborator OTHER
  • National University Hospital, Singapore

    lead OTHER

Principal Investigators

  • Arthur Mark Richards, MBChB, MD (Distinction), PhD · University of Otago, Christchurch

  • Henry Krum, MBBS, PhD, FRACP, FCSANZ · Monash University

  • Carolyn Lam Su Ping, MBBS, MRCP, MS · National University Heart Centre, Singapore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-12-31
Completion
2016-12-31

Countries

  • Australia
  • New Zealand
  • Singapore

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02041130 on ClinicalTrials.gov